SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity
Author:
Yajima Yuki,
Kosaka AkemiORCID,
Ohkuri TakayukiORCID,
Hirohashi Yoshihiko,
Li Dongliang,
Nagasaki Takeshi,
Nagato Toshihiro,
Torigoe Toshihiko,
Kobayashi Hiroya
Subject
Multidisciplinary
Reference32 articles.
1. Clinical features of 69 cases with coronavirus disease 2019 in wuhan, China;Wang;Clin. Infect. Dis.,2020
2. Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19;Imran;Molecules,2021
3. Prevention and attenuation of covid-19 with the BNT162b2 and mRNA-1273 vaccines;Thompson;N. Engl. J. Med.,2021
4. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data;Haas;Lancet,2021
5. Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the United States;Tenforde;Clin. Infect. Dis.,2022